Brind.
  1. Silexion Therapeutics Corp. announced a reverse share split to preserve its Nasdaq listing, focusing on RNAi therapies for KRAS-driven cancers.

Silexion Therapeutics Corp. pioneers RNAi therapies for KRAS-driven cancers, establishing partnerships with AMS and Catalent.

4 reports, 1 independent Updated Sep 4
Gone quiet
Reports
4
Developments
2
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Silexion Therapeutics Corp. pioneers RNAi therapies for KRAS-driven cancers, establishing partnerships with AMS and Catalent.

Who's involved

What this event is mainly about
KrasAMSCatalent (United Kingdom)

How it developed

Newest first. Tap a step to see who reported it.
  1. Silexion partners with AMS (CRO) and Catalent (manufacturing) for KRAS RNAi trials.1 source
  2. Silexion Therapeutics Corp. is developing RNAi therapies for KRAS-driven cancers and utilizes a facility in Limoges for clinical manufacturing.1 source

Keep exploring

Part of

Silexion Therapeutics Corp. announced a reverse share split to preserve its Nasdaq listing, focusing on RNAi therapies for KRAS-driven cancers. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireSilexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204 Strategic CRO to Support Path to Phase 2/3 Trials Following Recent
  • GlobeNewswireSilexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Continued advancement of SIL204 preclinical program with strong efficacy data across multiple KRAS-dri
  • GlobeNewswireSilexion Therapeutics Announces 1-for-15 Reverse Share Split Trading on split-adjusted basis will begin at market open on July 29, 2025. This adjustment is expected to help Silexion comply with NASDA
  • Unknown outlet